 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910111213» |
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Journal: Prediction and primary prevention of major vascular complications in systemic sclerosis. (Pubmed Central) - Jun 1, 2021
in SSc patients, our data confirm the role of arthritis and dyspnea as independent predictors of major vascular complications, in particular in MVCs-naïve patients. Prostanoids, sildenafil and ARBs, even in absence of a primary preventive action, might help in slowing disease progression and postponing the onset of MVCs.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Preclinical, Journal, IO biomarker: Iloprost affects in vitro maturation and developmental competence of bovine oocytes. (Pubmed Central) - May 28, 2021
Although, iloprost-enhanced maturation had no direct effect on number of embryos cleaved, it increased blastocyst rates of bovine embryos as well as proportion of expanded blastocysts. These results indicate that the supplementation of maturation medium with iloprost is beneficial for the maturation efficiency and developmental competence of bovine oocytes.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Efficacy and safety of iloprost in patients with septic shock-induced endotheliopathy - protocol for the multicenter randomized, placebo-controlled, blinded, investigator-initiated COMBAT-SHINE trial. (Pubmed Central) - May 22, 2021
P2/3
This trial test the safety and efficacy of iloprost vs. placebo for 72-hours in patients with septic shock and SHINE. The outcome measures focus on the potential effect of the intervention to mitigate organ failure.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets. (Pubmed Central) - May 22, 2021
Genetic deletion of TSP-1 did not affect platelet activation in vitro, but in vivo models of hemostasis and thrombosis showed that TSP-1-deficient mice had prolonged bleeding, defective thrombosis, and increased sensitivity to the prostacyclin mimetic iloprost...Platelets deficient in CD36, a TSP-1 receptor, showed increased sensitivity to PGI2/cAMP signaling and diminished PDE3A activity, which was unaffected by platelet-derived or purified TSP-1. This scenario suggests that the release of TSP-1 regulates hemostasis in vivo through modulation of platelet cAMP signaling at sites of vascular injury.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] INTRAVENOUS ILOPROST: A REGION WIDE SURVEY OF CURRENT PRESCRIBING AMONGST HOSPITALS IN THE WESSEX MULTI-DISCIPLINARY CONNECTIVE TISSUE DISEASE NETWORK () - May 21, 2021 - Abstract #EULAR2021EULAR_2744;
Most of this group of patients would likely be eligible for treatment with sildenafil or bosentan. Sildenafil intolerance is a challenge to management.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] ACCESS TO TREATMENT FOR RAYNAUD’S PHENOMENON AND DIGITAL ULCERS FOR PATIENTS WITH SYSTEMIC SCLEROSIS DOESN’T FOLLOW EULAR/EUSTAR GUIDELINES () - May 21, 2021 - Abstract #EULAR2021EULAR_2694;
Intravenous prostanoid infusions are difficult to obtain and have system barriers. Advocacy and cost effectiveness data should be used to advocate for access to medications that are recommended within SSc recommendations.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] RAYNAUD’S PHENOMENON IN A SINGLE CENTER COHORT OF TURKISH CHILDREN (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_3664;
In patients with secondary RP, the symptoms. It has been shown that in patients with secondary RP, symptoms begin at a younger age and the ANA positivity and abnormal nailfold capillaries correlate.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] EFFECTS OF SERIAL LOCALLY APPLIED WATER-FILTERED INFRARED A RADIATION IN PATIENTS WITH SYSTEMIC SCLEROSIS WITH SEVERE RAYNAUD’S SYNDROME RECEIVING PROSTAGLANDINE TREATMENT – A RANDOMIZED CONTROLLED TRIAL (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2783;
It has been shown that in patients with secondary RP, symptoms begin at a younger age and the ANA positivity and abnormal nailfold capillaries correlate. The additive and frequent use of sl-wIRAR in the treatment of SSc patients with RS requiring Iloprost treatment does not improve outcomes regarding pain levels, RS intensity or frequency nor IL-6 and VEGF levels when compared to Iloprost treatment and low-frequent hyperthermia application.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] AMINAPHTONE LONG-TERM TREATMENT IN SYSTEMIC SCLEROSIS (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2769;
During an average observation period of three years, Aminaphtone showed a good tolerability profile along with sustained efficacy in 94% of patients with SSc-related RP, without disabling side effects. The absence of a placebo-control group, the retrospective design limit the results, and a randomized controlled trial for Aminaphtone use in the management of SSc-related RP is needed.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Inhibition of the Proliferation of Human Lung Fibroblasts by Prostacyclin Receptor Agonists is Linked to a Sustained cAMP Signal in the Nucleus. (Pubmed Central) - May 20, 2021
This suggests that sustained elevation of cAMP in the nucleus is necessary for efficient inhibition of PDGF-induced nuclear ERK and fibroblast proliferation. This is an important first step towards understanding of the signalling events that drive GPCR inhibition of fibrosis.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Iloprost: a potential alternative for skin graft-resistant hypertensive leg ulcer. (Pubmed Central) - May 15, 2021
Surgical management with grafts is recommended to control pain and promote healing. However, with treatment failure, there are unmet therapeutic needs.
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Differing commissioning arrangements may contribute to geographic variation in clinical management of digital ulcers in systemic sclerosis. (Pubmed Central) - May 15, 2021
Bosentan use for SSc-DU after 2015 in SW England increased, while remaining stable and proportionately lower in Wales. These findings demonstrate that differing commissioning guidance across devolved nations of the UK seems to contribute to geographic variation in patient care.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen, Simdax (levosimendan IV) / AbbVie
Review, Journal: Inhaled pulmonary vasodilators: a narrative review. (Pubmed Central) - May 15, 2021
The literature suggests that inhaled aerosolized epoprostenol, iloprost, treprostinil and others such as milrinone and levosimendan may be similar to iNO. More research of IPV is needed to determine acceptable inclusion criteria, long-term outcomes, and management strategies including time, dose, and duration.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] A rare cause of diffuse peripheral and central thromboses () - May 12, 2021 - Abstract #BSH2021BSH_500;
A triphasic finger colour change was noted with livedo reticularis on her lower limbs; a decision to institute Iloprost and Methylprednisolone ensued...Management subsequently included the addi- tion of Rituximab, Plasma Exchange, IVIG and Sildenafil...Finally, the risk of immunosuppression for patients who have received Rituximab can persist for up to 12 months following treatment. This patient’s risk stratification was high in view of COVID-19 and she was advised to shield until government guideli- nes ended.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis. (Pubmed Central) - May 11, 2021
In general, worldwide expert agreement on updated recommendations for treatment of SSc is high, supporting their value. Differences in agreement are partially explained by geographical area and treatment availability.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Clinical data, Journal: Evaluation of Clinical Outcomes After Revascularization in Patients With Chronic Limb-Threatening Ischemia: Results From a Prospective National Cohort Study (RIVALUTANDO). (Pubmed Central) - May 11, 2021
Results from this prospective multicenter registry offer a consistent overview of clinical outcomes of CLTI patients at 1 year when adequately revascularized. Medical treatment, including statins, cilostazol and iloprost, were associated with improved 1-year freedom from restenosis and amputation.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Iloprost in COVID-19: The Rationale of Therapeutic Benefit. (Pubmed Central) - May 11, 2021
Medical treatment, including statins, cilostazol and iloprost, were associated with improved 1-year freedom from restenosis and amputation. No abstract available
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity. (Pubmed Central) - May 4, 2021
In conclusion, EVs released following monocyte/platelet activation may play a potential role in the development and progression of atherosclerosis. Whereas attenuating platelet activation modifies EV composition released from monocyte/platelet aggregates, curbing their pro-inflammatory actions may offer therapeutic avenues for the treatment of atherosclerosis.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Bronchodilation induced by PGE is impaired in Group-III pulmonary hypertension. (Pubmed Central) - Apr 10, 2021
This study shows that PGI -mimetics have preserved maximal bronchodilation in PH-Group III patients. The decreased bronchodilation induced by EP4 agonists suggests that restoration of EP4 expression in airways of PH-patients with respiratory diseases could bring additional therapeutic benefit.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Journal: The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial. (Pubmed Central) - Apr 7, 2021
P3
The decreased bronchodilation induced by EP4 agonists suggests that restoration of EP4 expression in airways of PH-patients with respiratory diseases could bring additional therapeutic benefit. The trial aims to provide evidence on the efficacy and safety of Ilomedin in patients with septic shock and persistent microcirculatory disorders.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension. (Pubmed Central) - Apr 7, 2021
All prostacyclin analogues delayed thrombus formation and decreased thrombus size (p ≤ 0.04). (5) PAH patients treated with prostacyclin analogues had impaired platelet reactivity, EV release, and thrombus formation, compared to patients not receiving prostacyclin analogues.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] INTERNATIONAL MULTICENTRIC PROSPECTIVE STUDY ON PREGNANCY IN SYSTEMIC SCLEROSIS (IMPRESS-2) (Room 12) - Apr 6, 2021 - Abstract #EULAR2021EULAR_1415;
SSc pregnancies have generally a favorable obstetric/pediatric outcome, albeit at a higher risk of gestational hypertension, pre-eclampsia, fetal growth restriction, prematurity, delivery of SGA newborn and requirement of neonatal-ICU. Pregnancy does not impact on SSc course, although SRC during late pregnancy and pre-eclampsia might be hardly discriminated.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Dissecting the cellular mechanism of prostacyclin analogue iloprost in reversing vascular dysfunction in scleroderma. (Pubmed Central) - Mar 23, 2021
Our data suggests that the long-lasting effects of iloprost reflect its ability to stabilize adherens junctions, resulting in increased tubulogenesis and barrier function, and reduced Endo-MT. These results provide a mechanistic basis for the use of iloprost in treating SSc patients with RP and DU.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Review, Combination therapy: Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia (Pubmed Central) - Mar 23, 2021
Some beneficial pharmacological effects due to the synergy between ambrisentan plus riociguat, and inhaled iloprost plus sildenafil appear to be interesting and require further clinical confirmation. Other initial combinations of PAH-specific agents require large-scale clinical trials as well.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal, Combination therapy: Inhaled Iloprost and Oral Sildenafil Combination Therapy: Is it a Chance for Heart Transplant Candidacy? (Pubmed Central) - Mar 17, 2021
After a decrease in PVR with ilo-sil combination therapy for patients with severe pulmonary hypertension, these patients may become candidates for heart transplant without bearing additional risk. Ilo-sil combination therapy could be a viable option with which to evaluate the reversibility of PVR.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] Loss of Frizzled 9 Alters Lung Epithelial Cell Signaling Pathways and Interferes with the Protective Effect of Iloprost Chemoprevention () - Mar 14, 2021 - Abstract #ATS2021ATS_4943;
Alteration of gene expression with Fzd9 loss and after urethane exposure indicates possible mechanisms for effects of Fzd9 in the lung epithelium, including a potential interaction with estrogen receptor signaling. These studies are an important translational step toward understanding and precisely applying lung cancer chemoprevention in high-risk populations and exploring the potential role of Fzd9 as a response prediction biomarker.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
[VIRTUAL] Inhaled Prostacyclin Prevents Urethane Induced Lung Adenocarcinoma () - Mar 14, 2021 - Abstract #ATS2021ATS_2376;
Moreover, IL1β gene expression was significantly reduced in iloprost treated mice, suggesting an immune regulatory role. This chemoprevention model will be a valuable tool for investigating mechanisms of inhaled iloprost chemoprevention complemented by our ongoing clinical trial.
- Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen, Uptravi (selexipag) / J&J, Nippon Shinyaku
[VIRTUAL] Real-World Experience of Selexipag in Patients with Pulmonary Arterial Hypertension in an Irish Center () - Mar 14, 2021 - Abstract #ATS2021ATS_66;
Conclusion This is the first study of real-world experience of selexipag in Ireland and demonstrates that selexipag can be safely initiated, titrated and transitioned in an outpatient setting to achieve an individualised dosing regimen. Close observation and consideration of clinical, biochemical and hemodynamic parameters are recommended following any changes in baseline drug therapy.
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date: SHINE-TRAUMA: Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure (clinicaltrials.gov) - Mar 10, 2021
P2, N=220, Recruiting, Sponsor: P
Close observation and consideration of clinical, biochemical and hemodynamic parameters are recommended following any changes in baseline drug therapy. Trial primary completion date: Apr 2021 --> Jul 2021
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed, Trial primary completion date: COMBAT-COVID: Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure (clinicaltrials.gov) - Mar 10, 2021
P2, N=80, Active, not recruiting, Sponsor: P
Trial primary completion date: Apr 2021 --> Jul 2021 Recruiting --> Active, not recruiting | Trial primary completion date: May 2021 --> Feb 2021
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Preclinical, Journal: Effects of iloprost on experimental ischemia and reperfusion injury in rat ovary. (Pubmed Central) - Mar 4, 2021
The GSH level was higher in the I/R + iloprost group than in the I/R group. We concluded that IV iloprost administration reduces I/R injury in rat ovarian tissue.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, P2 data, Journal: Low dose Iloprost effect on platelet aggregation in comatose out-of-hospital cardiac arrest patients: A predefined sub-study of the ENDO-RCA randomized -phase 2- trial. (Pubmed Central) - Mar 2, 2021
P2
There was no increased risk of bleeding or transfusion therapy. A decline in platelet aggregation was observed for the ASPI and ADP assays during the initial 96 h after OHCA.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: The Cell Cycle Checkpoint System MAST(L)-ENSA/ARPP19-PP2A is Targeted by cAMP/PKA and cGMP/PKG in Anucleate Human Platelets. (Pubmed Central) - Feb 20, 2021
Low-dose OA treatment of platelets caused PP2A inhibition, diminished thrombin-stimulated platelet aggregation and increased phosphorylation of distinct sites of VASP, Akt, p38 and ERK1/2 MAP kinases. In summary, our data establish the entire MASTL(like)-ENSA/ARPP19-PP2A pathway in human platelets and important interactions with the PKA, MAPK and PI3K/Akt systems.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Transcriptomic Signatures and Functional Network Analysis of Chronic Rhinosinusitis With Nasal Polyps. (Pubmed Central) - Feb 20, 2021
Repurposing drug candidates (Alfadolone, Hydralazine, SC-560, Iopamidol, Iloprost, etc) for CRSwNP treatment were identified from the Connectivity Map (CMap) database. Our results suggest multiple molecular mechanisms, diagnostic biomarkers, potential therapeutic targets, and new repurposing drug candidates for CRSwNP treatment.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: New approaches for the assessment of platelet activation status in thrombus under flow condition using confocal microscopy. (Pubmed Central) - Feb 4, 2021
Ilo (3.6 ng/ml, 36 ng/ml) decreased the thrombus area but at 36 ng/ml increased the platelet activation index. We showed that intravital models and flow chamber provide a detailed assessment of platelet activation status and the mechanism of drug action.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Journal: Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension. (Pubmed Central) - Feb 4, 2021
However, there is a lack of evidence concerning some of the drug combinations currently employed. We demonstrate the clinical and hemodynamical benefits of inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension. (Pubmed Central) - Jan 29, 2021
The genetic variants of PTGIS predispose pulmonary vascular responses to the iloprost stimulation. These findings suggest that PTGIS variants may be involved in the pathogenesis of IPAH.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Biomarker, Clinical, Journal: Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response. (Pubmed Central) - Jan 26, 2021
Inhalation of iloprost aerosol improved the hemodynamic parameters for all patients...AVT parameters, including pre-AVT, post-AVT and ΔAVT, have a more important prognostic value than currently used for identify a small subgroup of patients with PAH who are suitable for high-dose calcium channel blockers. Sex differences in AVT parameters suggest that sex should be taken into account in estimating prognosis.
- |||| Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical: @AWBeckMD you’re running a #vascular surgery crash course and a recert board examination with these challenging cases! 💪🏽👏🏽👏🏽 Buerger’s disease. Smoking cessation. Antiplatelet and statin. Iloprost. (Twitter) - Jan 24, 2021
- |||| Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical: Nice educational case, Buerger disease and trx with smoking cessation, iloprost, maybe HBOT? (Dr. Tripathi gave good hints 😁) (Twitter) - Jan 24, 2021
- |||| Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical: Smoker? Cork screw collaterals. Young patient. One leg lost. Therapeutic LMWH + Iloprost for a week then re-angio. (Twitter) - Jan 24, 2021
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation. (Pubmed Central) - Jan 23, 2021
Gliflozins (canagliflozin, dapagliflozin and empagliflozin) are the newest anti-hyperglycemic class and have offered cardiovascular and renal benefits...Aggregation, flow cytometry for glycoprotein IIb/IIIa, cyclic nucleotides and intracellular calcium levels, Western blot, thromboxane B (TXB) measurement and COX-1 activity were performed in the presence of gliflozins (1-30 μM) alone or in combination with sodium nitroprusside (SNP, 10 or 100 nM) + iloprost (ILO, 0.1 or 1 nM)...The intracellular levels of cAMP and cGMP and the protein expression of p-VASPSer157 and p-VASPSer239 were not increased by gliflozins while the expression of the serine-threonine kinase, AktSer473 was markedly reduced. Our results showed that the antiplatelet activity of gliflozins were greatly enhanced by nitric oxide and prostacyclin, thus suggesting that the cardiovascular protection seen by this class of drugs could be in part due to platelet inhibition.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Review, Journal: Interventions for frostbite injuries. (Pubmed Central) - Jan 16, 2021
However, buflomedil has been withdrawn from use. High quality randomised trials are needed to establish firm evidence for the treatment of frostbite injuries.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. (Pubmed Central) - Jan 13, 2021
Existing therapeutic limitations indicate that more evidence-based treatment is warranted for successful management of SSc. Vasculopathy seems to be managed more rigorously, but the low retention rates of immunosuppressive/antiproliferative drugs suggest that effective and targeted disease-modifying agents are warranted.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Efficacy and safety of iloprost in trauma patients with haemorrhagic shock induced endotheliopathy - protocol for the multicenter randomized, placebocontrolled, blinded, investigator-initiated SHINE-TRAUMA trial. (Pubmed Central) - Jan 5, 2021
Secondary endpoints include 28 and 90-day all-cause mortality, hospital length of stay, vasopressor-free days in the intensive care unit (ICU) within 28 days, ventilator-free days in the ICU within 28 days, renal replacement free days in the ICU within 28 days, number of serious adverse reactions and serious adverse events within the first 4 days of admission This trial will test the safety and efficacy of administration of iloprost vs. placebo for 72-hours in trauma patients with haemorrhagic shock induced endotheliopathy. Trial endpoints focus on the potential effect of iloprost to reduce the need for ICU stay secondary to mitigation of organ failure.
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
@DrThomasTorok @SavesCpr @aayshacader @counts_cpr @YAS_HelenS @aridanyromero @imd_lpgc @HidalgoAlcalde @AyuntamientoLPA @AustinChiangMD @VietHeartPA @Barbara_Casadei @rahatheart1 @OSUCardioOnc @rbcasado @ACCCardioEd @ARSSeNaSaRD @DaniloMedina (Twitter) - Jan 4, 2021
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, P2 data, Journal: Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study. (Pubmed Central) - Dec 30, 2020
P3
Trial endpoints focus on the potential effect of iloprost to reduce the need for ICU stay secondary to mitigation of organ failure. The results of the ThIlo trial will highlight the anti-inflammatory effect of iloprost on early inflammatory processes during ARDS, resulting in the improvement of outcome parameters in patients with ARDS.
- | Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Biomarker, Journal: Usefulness of mean pulmonary artery pressure for predicting outcomes of transcatheter closure of atrial septal defect with pulmonary arterial hypertension. (Pubmed Central) - Dec 23, 2020
The results of the ThIlo trial will highlight the anti-inflammatory effect of iloprost on early inflammatory processes during ARDS, resulting in the improvement of outcome parameters in patients with ARDS. This large-scale study indicated that MPAP could be a simple but powerful index to predict benefit from closure in adult ASD patients with PAH.
- ||| Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
@OSUCardioOnc @rbcasado @ACCCardioEd @ARSSeNaSaRD @DaniloMedina @EducacionRDo @heartcaredom @JuventudRD @rd_mca @SaludPublicaRD @sccccardio @secardiologia @SIAC_cardio (Twitter) - Dec 23, 2020
- || Ventavis (iloprost ) / Bayer, J&J, University of Copenhagen
Clinical, Journal: Impaired iloprost-induced platelet inhibition and phosphoproteome changes in patients with confirmed pseudohypoparathyroidism type Ia, linked to genetic mutations in GNAS. (Pubmed Central) - Dec 23, 2020
In one patient with GNAS mutation, diagnosed as non-AHO, the changes in platelet phosphoproteome were reversed. This combined approach thus revealed multiple phenotypic and molecular biomarkers to assist in the diagnosis of suspected PHP Ia.